With this investigation, we investigated on the contribution of lncRNA MALAT1 to inflammation disorder in Parkinson's Disease (PD). Serum samples were gathered from sporadic PD patients and healthy controls, and single nucleotide polymorphisms (SNPs) of MALAT1, including rs11227209, rs3200401, rs4102217, rs591291, rs619586 and rs664589, were identified. Serum level of MALAT1 was quantified using RT-PCR, and IL-1β, IL-6, TNF-α and IFN-γ levels in serum were measured with ELISA kits. Inflammation cell models were established by treating PC12 cells with LPS, and cytokine production of pcDNA3.1-MALAT1/si-MALAT1-transfected PC12 cells was evaluated. The results showed that PD patients with high serum level of MALAT1 were associated with lower MMSE score and higher serum levels of IL-1β, IL-6, TNF-α and IFN-γ than patients carrying low serum level of MALAT1 (p < .05). Mutant alleles of SNPs in MALAT1, including rs3200401 (C>T) and rs4102217 (G>C), tended to elevate PD susceptibility and facilitate cytokine production, as compared with their wild alleles (p < .05). And LPS-exposed PC12 cells secreted larger amounts of inflammation cytokines in the pcDNA3.1-MALAT1 group than in the Mock group (p < .05). In conclusion, MALAT1 participated in modifying inflammation disorder underlying PD aetiology, suggesting that it might be a promising therapeutic target for PD.

中文翻译：

---

LncRNA MALAT1 增强帕金森病的炎症障碍

通过这项调查，我们调查了 lncRNA MALAT1 对帕金森病 (PD) 炎症障碍的贡献。从散发性 PD 患者和健康对照中收集血清样本，并鉴定了 MALAT1 的单核苷酸多态性 (SNP)，包括 rs11227209、rs3200401、rs4102217、rs591291、rs619586 和 rs664589。使用 RT-PCR 定量血清 MALAT1 水平，并使用 ELISA 试剂盒测量血清中 IL-1β、IL-6、TNF-α 和 IFN-γ 水平。通过用 LPS 处理 PC12 细胞建立炎症细胞模型，并评估 pcDNA3.1-MALAT1/si-MALAT1 转染的 PC12 细胞的细胞因子产生。结果表明，血清 MALAT1 水平高的 PD 患者与较低的 MMSE 评分和较高的血清 IL-1β、IL-6、p  < .05)。与野生等位基因相比，MALAT1 中 SNP 的突变等位基因，包括 rs3200401 (C>T) 和 rs4102217 (G>C)，倾向于提高 PD 易感性并促进细胞因子的产生 ( p  < .05)。在 pcDNA3.1-MALAT1 组中，LPS 暴露的 PC12 细胞比 Mock 组分泌更多的炎症细胞因子 ( p  < .05)。总之，MALAT1 参与了改变 PD 病因的炎症障碍，这表明它可能是一个有前途的 PD 治疗靶点。